Aligos Therapeutics (ALGS) Return on Equity (2021 - 2025)
Historic Return on Equity for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 1.0%.
- Aligos Therapeutics' Return on Equity rose 3200.0% to 1.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.0%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 4.16% for FY2024, which is 32600.0% down from last year.
- Latest data reveals that Aligos Therapeutics reported Return on Equity of 1.0% as of Q3 2025, which was up 3200.0% from 0.68% recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' Return on Equity registered a high of 0.64% during Q4 2021, and its lowest value of 12.42% during Q4 2024.
- For the 5-year period, Aligos Therapeutics' Return on Equity averaged around 1.73%, with its median value being 1.03% (2023).
- Per our database at Business Quant, Aligos Therapeutics' Return on Equity plummeted by -112300bps in 2024 and then soared by 5100bps in 2025.
- Over the past 5 years, Aligos Therapeutics' Return on Equity (Quarter) stood at 0.64% in 2021, then plummeted by -33bps to 0.85% in 2022, then crashed by -40bps to 1.19% in 2023, then plummeted by -941bps to 12.42% in 2024, then soared by 92bps to 1.0% in 2025.
- Its Return on Equity was 1.0% in Q3 2025, compared to 0.68% in Q2 2025 and 1.22% in Q1 2025.